NEOTIGHT® REJUVENATING ANTI-WRINKLE SERUM

One application. A measurable gain in elasticity.

Within one hour, independent instrumental testing measured a significant improvement in net elasticity, while expert grading separately documented firmer-looking skin. By Week 6, expert line grades and participant feedback supported improved-looking lines and more youthful-looking skin.

33 completed | 1-hour + 6-week results | Instrument + expert grading | Tested as SGF20055-00

7.65%

improvement in net elasticity

1 HOUR

Cutometer R5, n=32; p=0.015.

24.53%

improvement in crow's-feet appearance

WEEK 6

Expert-graded mean change, n=31; no p-value reported.

96.88%

said the product hydrated skin well

WEEK 6

Participant perception, n=32.

IMMEDIATE + PROGRESSIVE PERFORMANCE

A rapid elasticity result, followed by visible and perceived improvement.

MEASURED AFTER ONE APPLICATION

Cutometer R5 net elasticity improved 7.65% one hour after application (n=32; p=0.015). In a separate expert assessment, firmer-looking skin improved 12.05% at the same visit (n=31; descriptive mean change).

Crow's-feet appearance **24.53%**

Week 6 expert-graded mean improvement, n=31; no p-value reported.

Upper-lip line appearance **13.64%**

Week 6 expert-graded mean improvement, n=31; no p-value reported.

Nasolabial-fold appearance **7.14%**



Week 6 expert-graded mean improvement, n=31; no p-value reported.

87.50%
said overall skin appearance improved.

84.38%
said fine lines and wrinkles looked reduced.

78.13%
saw reduced crow's-feet appearance.

71.88%
noticed a firmer-looking, lifted appearance.

CONSUMER PERCEPTION

Week 6 questionnaire results are self-reported agreement among 32 respondents and are shown separately from instrument and expert assessments.

TECHNICAL STUDY RECORD

A signed final source supports a precise one-hour claim and a complementary six-week appearance story.

INDEPENDENT LABORATORY Validated Claim Support, LLC	STUDY / REPORT CS201033 / RE201033.V02
TESTED ARTICLE Rejuvenating Anti-Wrinkle Serum Formula SGF20055-00	DESIGN 6-week single-arm baseline comparison
POPULATION 34 enrolled; 33 completed; ages 48-69	USE 2-3 pumps, twice daily
EVIDENCE Cutometer, Visioscan, expert grading, photography, questionnaire	SOURCE DATE 13 November 2020

Instrumental context

Assessment	Baseline	Follow-up	Source-reported mean % improvement	p-value
Cutometer R5 net elasticity	0.5023	0.5407 at 1 hour	+7.65%	0.015
Cutometer R0 firmness	0.2966	0.3326 at 1 hour	-12.12% (unfavorable)	0.011
Visioscan crow's-feet SEw	185.89	166.23 at Week 6	-10.57%	0.278
Visioscan nasolabial-fold SEw	206.78	174.54 at Week 6	-15.59%	0.156

For R5, increase indicates improvement; for R0 and SEw, decrease indicates improvement. The statistically significant R5 net-elasticity response at 1 hour is the primary instrumental result; additional endpoints are included for complete study context.

STUDY APPLICATION

Expert-graded appearance and participant-perception results are presented separately from the instrument findings. Results apply to Rejuvenating Anti-Wrinkle Serum Formula SGF20055-00 under the reported six-week study design.

INDEPENDENT LABORATORY EVIDENCE

Original source pages follow.

Selected original VCS pages follow, preserving the cover, study design, selected aggregate results, conclusion, authorization, and Quality Assurance evidence while excluding participant-level listings.

LABORATORY	STUDY / REPORT
Validated Claim Support, LLC	CS201033 / RE201033.V02
SOURCE DATE	**AUTHENTICATION**
13 November 2020	Investigator authorization + independent QA/QC

SOURCE AUTHENTICATION

The final report includes dated study authorization and a separate independent QA/QC certification completed in November 2020.

SOURCE NOTE

The 1-hour timing shown in the summary follows the study schedule and Cutometer results table. Participant-level Cutometer rows were removed from the appended result page; aggregate Average and Statistical Analysis rows are unchanged.

Independent laboratory source pages are included in the complete PDF. Participant-identifying information has been removed where indicated; aggregate findings are unchanged.

STUDY REPORT

1. Report Summary:

Study Title:	6 Week Evaluation of An Anti-Aging Product
Sponsor:	SeneGence 19651 Alter Foothill Ranch, California 92610
Test Article:	Rejuvenating Anti-Wrinkle Serum Formula # SGF20055-00
VCS Sample No.:	SA201036
VCS Clinical Study No.:	CS201033
Study Initiation Date:	9 July 2020
Study Completion Date:	28 August 2020
Subjects Reported:	30-33
Version:	Final
Study Location:	Validated Claim Support, LLC 400 Frank W. Burr Boulevard Suite 105 Glenpointe Atrium Teaneck, New Jersey 07666
Study Design:	Test product was evaluated at 1 Hour, Week 3, and Week 6 using Qualitative Questionnaire, Expert Grading, as well as instrumental measurements via Visioscan, Cutometer, and Clinical Photography.

2. Key Study Personnel and Responsibilities:

Principal Investigator:	Anna Hardy
Clinical Photographer:	James VanZetta
Technicians:	Chrystal Planeta, Janice Yalong, & Surina Chock

3. Introduction and Objective:

This panel was convened to evaluate the efficacy of a test material intended to improve skin elasticity, fine lines and wrinkles on the face over a period of 6 weeks.

4. Test Material Handling:

Upon reception of samples at VCS on 6 July 2020, the test material was assigned a unique code and digitally logged into the system. Products were stored in a secure location and unused products were returned to Sponsor or discarded upon issue of final report.

5. Safety Prerequisite:

Sponsor purports that toxicology, microbiology, preservative efficacy, and/or other in-vitro/in-vivo safety and performance analyses were conducted as required by law or as recommended by legal council and that the test article does not contain antibiotics, antiseptics, steroids, hormones, or any other substances at levels of concentration requiring label declaration by the relevant regulatory authorities.

6. Selection of Subjects:

6.1. Screening

Subjects Enrolled (see Subject Demographics – Appendix 1)	34
Subjects Completed	33
Subjects Reported	30-33

All subjects enrolled into the study completed VCS required documentation, have been assigned an MRN (Medical Record Number, a unique identification number), satisfied the study specific inclusion and exclusion criteria, and gave their written informed consent.

6.2. Inclusion Criteria

- Female subjects in good general health, aged 30-70 years old, that identify as one or more of the following:
  - Caucasian
  - Asian
  - Black/African American
  - American Indian/Alaska Native
  - Native Hawaiian/Pacific Islander
  - Hispanic

- Individuals who are able to cooperate with the Principal Investigator and study personnel throughout the duration of the study and are willing to comply with all study procedures, methods, evaluations, and study product use.
- Individuals who are able to read, understand and willing to sign an informed consent for this specific study and have completed all VCS required documentation prior to study enrollment (Registration, Medical History, and PRI).
- Individuals willing to be photographed and sign a model release.
- Individuals who have self-perceived aging skin including but not limited to crow's feet, nasolabial folds, upper lip lines, and lack of firmness.

6.3. Exclusion Criteria

- Individuals with acute or chronic disease(s) or medical condition(s), including dermatological problems, which could put them at risk in the opinion of the Principal Investigator or compromise the study outcome. Typical uncontrolled chronic or serious diseases and conditions which would prevent participation in any clinical study are cancer, AIDS, insulin dependent diabetes, renal impairment, mental illness, and/or drug/alcohol addiction.
- Individuals with a history of melanoma, or a treated skin cancer within the last 5 years.
- Individuals who are pregnant, lactating, or planning to become pregnant. Individuals who become pregnant during the study must inform the Principal Investigator immediately.
- Individuals who are unreliable or unlikely to be available for the duration of the study.
- Individuals with a history of allergic reactions, skin sensitization and/or known allergies to cosmetic and personal care products/ingredients.
- Individuals who are immunocompromised.
- Individuals who are employees of VCS or other testing firms/laboratories, cosmetic or raw goods manufacturers or suppliers.
- Individuals who are unable to communicate or cooperate with the Principal Investigator/study personnel due to language problems, poor mental development, or impaired cerebral function.
- Individuals who started Hormone Replacement Therapy within the last three months preceding the commencement of the study.
- Individuals who are using oral contraception for less than three months before study commencement or who have changed their contraceptive method within the three months before the Baseline visit or planning to modify their contraception treatment within the duration of the study.
- Individuals who have traveled internationally or who have any immediate family/ household member who have travelled internationally 2 weeks prior to the screening visit and throughout the study.

- Individuals with COVID-19 related symptoms (fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and/or diarrhea) within 2 weeks prior to the screening visit and throughout the study.
- Individuals who have used a fever/pain reducer within 3 days prior to any site visit.

6.4. Prohibitions & Restrictions for the Duration of the Study

- Excessive/direct sun exposure for the purpose of tanning during the study.
- Use of self-tanning products or tanning beds during the study.
- Initiating the use of any new cosmetic/personal care products during the study.
- Using other anti-aging or skin firming products during the study.

7. Institutional Review Board:

IRB approval was not requested by the sponsor.

8. Methodology:

8.1. Study Design

A minimum of 30 healthy subjects who were willing to adhere to the specific study requirements were recruited into the study. Product effectiveness was evaluated using Qualitative Questionnaire and Expert Grading as well as instrumental measurements via Visioscan, Cutometer, and Clinical Photography. Product was weighed before distribution, at each intermediate visit and at the final visit during collection.

All panelists arrived with a clean face, free from any cosmetic, facial, or test product(s) for each study evaluation. Panelists were instructed to remove all make up the night before each evaluation visit. Panelists arrived for each evaluation after washing their face in the morning with their regular face wash. Panelist were instructed not to use the test product, any other cosmetic or facial products on evaluations days.

On Day 0 (Baseline), after acclimation and following completion of all baseline procedures, panelists applied the test product for the first time onsite under supervision of study personnel.

8.2. Use Instructions

Apply 2-3 pumps of the product, use twice a day (Morning & Night).

8.3. Study Schedule

Procedures	Pre-Study	Screening (-7 Day)	Baseline	1 Hour (±5 Mins)	Week 3 (±48 Hours)	Week 6 (±48 Hours)
VCS Panelist Registration	X					
Informed Consent		X				
Dispense/Collect Product			D			C
Qualitative Questionnaire				X		X
Expert Grading			X	X	X	X
Visioscan			X		X	X
Cutometer			X	X		
Clinical Photography (Subset 6)			X		X	X

8.4. Ambient Conditions

All evaluations were performed under controlled conditions at a temperature within the range of 20°C and 24°C (68°F and 75°F). Prior to baseline evaluation all panelists acclimatized to ambient conditions for at least 15 minutes.

8.5. Assessments

The devices used for this study are non-invasive and have no known risks associated with them.

Qualitative Questionnaire

All participants were asked to complete a qualitative questionnaire, pertaining to product use, and provide information about product effectiveness.

No.	1 Hour Questionnaire	Agree	Disagree
1	After only one application, I can see immediate improvement of the look of my skin.		
2	After only one application, my skin immediately felt firmer.		
3	After only one application, my skin immediately looked firmer.		
4	After only one application, my skin felt tighter.		
5	After only one application, my skin looked tighter.		
6	After only one application, my skin looked smoother.		

7	After only one application, my skin looked smoother and younger.		
8	After only one application, the test product significantly diminished the look of loose and baggy skin.		
9	Did you notice a firmer-looking & lifted appearance within 1 hour of application?		
10	Did you like the color, texture, smell, and feel of the product?		
11	Did you like how the skin feels immediately after applying the product?		
12	Did the product absorb well into the skin and does not feel greasy/tacky?		
13	Did the product hydrate your skin well?		
14	Did your skin tolerate the product well without any sensitivities?		
15	Did you like the product overall?		

No.	**Week 6 Questionnaire**	**Agree**	**Disagree**
1	The test product reduces the appearance of nasolabial folds.		
2	The test product reduces the appearance of upper lip lines.		
3	The test product reduces the appearance of crow's feet around the eyes.		
4	The test product reduces the appearance of fine lines and wrinkles.		
5	My face appears more youthful since using the test product.		
6	My skin feels firmer since using the test product.		
7	My skin appears tighter since using the test product.		
8	The test product improves skin's overall appearance.		
9	Did you like the color, texture, smell, and feel of the product?		
10	Did you like how the skin feels immediately after applying the product?		
11	Did the product absorb well into the skin and does not feel greasy/tacky?		
12	Did you layer other treatments on top of the product?		
13	If YES, did you notice a change in the performance of the product?		
14	Did the product hydrate your skin well?		
15	Did your skin tolerate the product well without any sensitivities?		
16	Did you like the product overall?		
17	The test product makes my face look:		

< 1 Year Younger	1-5 Years Younger	5-10 Years Younger	10-15 Years Younger	>15 Years Younger

18	Did you notice a firmer-looking & lifted appearance within 1 hour of application?		
19	If YES, how long did the tightening effect last?		

1-2 Hours	2-3 Hours	3-4 Hours

Expert Grading

Expert grading was conducted from images captured via Clinical Photography by study personnel. Expert Grading was conducted at the end of the study after all images are compiled. The following attributes were evaluated based on the grading scale below.

Skin Firmness:

0	Firm, Tight Appearance
1	Mild
2	Moderate
3	Moderately Severe
4	Severe, Loose, Sagging Appearance

Appearance of Fine Lines & Wrinkles*:

0	Absence of fine lines
1	Slightly visible fine lines
2	Clearly visible fine lines and/or wrinkles
3	Prominent wrinkles
4	Deep furrow

(Modified Fitzpatrick Wrinkle Grading Scale) *Used to grade 3 different areas: Crow's Feet, Nasolabial Folds, and Upper Lip Lines.

Ref. Michaels, Basil & Csank, George & Ryb, Gabriel & Eko, Frederick & Rubin, Abigail. (2012). Prospective Randomized Comparison of OnabotulinumtoxinA (Botox) and AbobotulinumtoxinA (Dysport) in the Treatment of Forehead, Glabellar, and Periorbital Wrinkles. Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery. 32. 96-102. 10.1177/1090820X11430685.

Visioscan®

Visioscan® VC 20 Plus (Courage + Khazaka Electronic GmbH) is used to obtain measurements of the skin surface. The Visioscan® VC 20 Plus uses a unique UVA-light video camera with high resolution to study the skin surface directly. The evaluation method SELS® (Surface Evaluation of the Living Skin) analyses the grey level distribution and allows the calculation of four clinical parameters to quantitatively and qualitatively describe the skin surface as an index: Skin smoothness (SEsm), Skin roughness (SEr), Scaliness (SEsc), Wrinkles (SEw). Measurements of the SELS® parameters are automatically performed after the image is taken. Crow's feet and nasolabial folds parameters are evaluated using SEw (higher visible wrinkles = higher the SEw) for this study.

The small hand-held camera is brought into contact with the clean designated test area. The image is captured. The location of each image remains constant for each timepoint. Panelists are instructed to sit comfortably and quietly, gently close their eyes, relax their face and remain still while the images are being taken. Measurements are taken from the

best representative side as determined by the technician. One image from each region is taken from each test subject according to following template:



Cutometer

The Cutometer MPA 580 (Courage + Khazaka, Germany) measures the viscoelastic properties of the skin by applying suction to the skin surface, drawing the skin into the aperture of the probe and determining the penetration depth using an optical measuring system.

The resistance of the skin to be sucked up by the negative pressure (firmness) and its ability to return to its original position (elasticity) are calculated and displayed as curves. The Cutometer outputs include many parameters of different portions of the measurement curve including of R0 (Uf, firmness), R2 (Ua/Uf, gross elasticity), R5 (Ur/Ue, net elasticity), R7 (Ur/Uf, elastic portion) and R9 (R3[last max amp]-R0[Uf], fatigue).

Elasticity is reported using the R5 (Ur/Ue) parameter, as the skin becomes more elastic this value will increase. Skin Firmness is reported using the R0 (Uf) parameter, as the skin becomes firmer this value decreases.

Two measurements from either the left or right side (based on randomization) are taken from each test subject according to following template:



10. Premature Termination or Suspension of the Study:

This study was not prematurely suspended or terminated by VCS or the Sponsor.

11. Study Ethics:

11.1. Good Clinical Practice (GCP)

The study was conducted in compliance with the main principles of Good Clinical Practice (GCP) under International Conference of Harmonisation (ICH) Harmonised Tripartite Guideline on GCP E6(2). The practices and procedures conducted during this study pertaining to informed consent, subject safety, investigator responsibility, and adverse event reporting is designed to comply with ICH E6.

11.1. COIVD-19 Safety

Coronavirus Disease 2019 (COVID-19) is a respiratory disease caused by a type of virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As a group of viruses, coronaviruses are common across the world. Typical symptoms of coronavirus infection include fever, shortness of breath, a cough that may progress to severe pneumonia causing shortness of breath and breathing difficulties, and a loss of or change in your normal sense of smell or taste.

COVID-19 is a new coronavirus. It is no longer designated as a high consequence infectious disease (HCID) but still requires a national, coordinated response. For most people, COVID-19 will be a mild illness but may result in pneumonia or severe acute respiratory infection for some people.

VCS has developed new safety procedures that follow all federal and local requirements and regulations and have implemented a number of additional recommendations to reduce the risk of transmission of this novel virus as described in VCS Standard Operating Procedure (SOP-017).

11.2. Informed Consent Form Process

A study-specific informed consent is obtained from each volunteer prior to initiating the study indicated herein, it describes the design, reasons for study, possible adverse effects, associated risks and potential benefits of treatment and their limits of liability. Subjects sign and date the informed consent document to indicate their authorization to proceed and acknowledge their understanding of the contents. Subjects are informed that they are free to withdraw from the study at any time without being obliged to give a reason. Reference 21 CFRCh.1 Part 50, Subpart B.

11.3. Declaration of Helsinki

The study conformed to the requirements of the Declaration of Helsinki and its subsequent amendments (*World Medical Association; 2013)*.

11.4. Indemnity Provision

The Sponsor is responsible, without regard to legal liability, and indemnifies VCS, or any of their respective officers or employees in the event of claims for compensation from subjects suffering injury or other deterioration in health or wellbeing as a result of participation in this study. An exception can occur when claims arise as a result of any negligent act or omission on the part of VCS employees or any persons undertaking or involved in the study by arrangement with VCS.

Prior to commencement of this in-vivo clinical study with VCS an indemnification agreement was signed by the sponsor.

12. Retention of Data:

All raw data generated by VCS during the course of the study, and including protocol and final report, is retained digitally by VCS for a period of 25 years as per regulatory guidelines.

Data is secured on premise and through cloud-based backups in confidence, and shared only with sponsor clients, regulatory bodies, and AIRB upon request.

13. Results:

No.	Questionnaire Summary 1 Hour (N=33)	Agree	Disagree
1	After only one application, I can see immediate improvement of the look of my skin.	66.67%	33.33%
2	After only one application, my skin immediately felt firmer.	78.79%	21.21%
3	After only one application, my skin immediately looked firmer.	75.76%	24.24%
4	After only one application, my skin felt tighter.	75.76%	24.24%
5	After only one application, my skin looked tighter.	78.79%	21.21%
6	After only one application, my skin looked smoother.	81.82%	18.18%
7	After only one application, my skin looked smoother and younger.	51.52%	48.48%
8	After only one application, the test product significantly diminished the look of loose and baggy skin.	45.45%	54.55%
9	Did you notice a firmer-looking & lifted appearance within 1 hour of application?	69.70%	30.30%
10	Did you like the color, texture, smell, and feel of the product?	90.91%	9.09%
11	Did you like how the skin feels immediately after applying the product?	81.82%	18.18%
12	Did the product absorb well into the skin and does not feel greasy/tacky?	72.73%	27.27%
13	Did the product hydrate your skin well?	90.91%	9.09%
14	Did your skin tolerate the product well without any sensitivities?	100.00%	0.00%
15	Did you like the product overall?	96.97%	3.03%

No.	Questionnaire Summary Week 6 (N=32)	Agree	Disagree	N/A
1	The test product reduces the appearance of nasolabial folds.	62.50%	37.50%	
2	The test product reduces the appearance of upper lip lines.	71.88%	28.13%	
3	The test product reduces the appearance of crow's feet around the eyes.	78.13%	21.88%	
4	The test product reduces the appearance of fine lines and wrinkles.	84.38%	15.63%	
5	My face appears more youthful since using the test product.	75.00%	25.00%	
6	My skin feels firmer since using the test product.	75.00%	25.00%	
7	My skin appears tighter since using the test product.	71.88%	28.13%	
8	The test product improves skin's overall appearance.	87.50%	12.50%	
9	Did you like the color, texture, smell, and feel of the product?	84.38%	15.63%	
10	Did you like how the skin feels immediately after applying the product?	84.38%	15.63%	
11	Did the product absorb well into the skin and does not feel greasy/tacky?	71.88%	28.13%	
12	Did you layer other treatments on top of the product? If yes, answer Q13	25.00%	75.00%	
13	**If YES**, did you notice a change in the performance of the product?	12.50%	12.50%	75.00%
14	Did the product hydrate your skin well?	96.88%	3.13%	
15	Did your skin tolerate the product well without any sensitivities?	96.88%	3.13%	
16	Did you like the product overall?	87.50%	12.50%	
17	Did you notice a firmer looking & lifted appearance after application? If yes, answer Q18	71.88%	28.13%	
18	If **YES**, how long did the tightening effect last?			

1-2 Hours	2-3 Hours	3-4 Hours	N/A
25.00%	28.13%	18.75%	28.13%

19	The test product makes my face look:				
< 1 Year Younger	1-5 Years Younger	5-10 Years Younger	10-15 Years Younger	>15 Years Younger	
46.88%	43.75%	6.25%	3.13%	0.00%	

Expert Grading Summary (N=31) Skin Firmness			
Grade / Description		**Baseline**	**1 Hour**
0	Firm, Tight Appearance	0.00%	0.00%
1	Mild	0.00%	3.23%
2	Moderate	45.16%	58.06%
3	Moderately Severe	41.94%	38.71%
4	Severe, Loose, Sagging Appearance	12.90%	0.00%
	Average	**2.68**	**2.35**
	Average % Improvement		***12.05%***



Expert Grading Summary (N=31) Appearance of Fine Lines & Wrinkles – Upper Lip				
Grade / Description		**Baseline**	**Week 3**	**Week 6**
0	Absence of fine lines	45.16%	45.16%	45.16%
1	Slightly visible fine lines	38.71%	38.71%	48.39%
2	Clearly visible fine lines and/or wrinkles	16.13%	12.90%	6.45%
3	Prominent wrinkles	0.00%	3.23%	0.00%
4	Deep furrow	0.00%	0.00%	0.00%
	Average Grade	**0.71**	**0.74**	**0.61**
	Average % Improvement		***-4.55%***	***13.64%***

Expert Grading Summary (N=31) Appearance of Fine Lines & Wrinkles – Nasolabial				
Grade / Description		**Baseline**	**Week 3**	**Week 6**
0	Absence of fine lines	16.13%	16.13%	19.35%
1	Slightly visible fine lines	19.35%	22.58%	22.58%
2	Clearly visible fine lines and/or wrinkles	38.71%	35.48%	32.26%
3	Prominent wrinkles	19.35%	22.58%	22.58%
4	Deep furrow	6.45%	3.23%	3.23%
	Average Grade	**1.81**	**1.74**	**1.68**
	Average % Improvement		***3.57%***	***7.14%***

Expert Grading Summary (N=31) Appearance of Fine Lines & Wrinkles – Crow's Feet				
Grade / Description		**Baseline**	**Week 3**	**Week 6**
0	Absence of fine lines	16.13%	19.35%	25.81%
1	Slightly visible fine lines	25.81%	32.26%	29.03%
2	Clearly visible fine lines and/or wrinkles	32.26%	35.48%	35.48%
3	Prominent wrinkles	23.58%	9.68%	9.68%
4	Deep furrow	3.23%	3.23%	0.00%
	Average Grade	**1.71**	**1.45**	**1.29**
	Average % Improvement		***15.09%***	***24.53%***



Cutometer Summary (N=32) R0 (Firmness) & R5 (Elasticity)							
No.	MRN	Baseline		1 Hour		% Improvement	
		R0 (Firmness)	R5 (Elasticity)	R0 (Firmness)	R5 (Elasticity)	R0 (Firmness)	R5 (Elasticity)
Participant-level rows removed from this public edition. Aggregate Average and Statistical Analysis rows remain unchanged below.							
Average		**0.2966**	**0.5023**	**0.3326**	**0.5407**	***-12.12%***	***7.65%***

Statistical Analysis		
Value	**R0**	**R5**
p	0.011*	0.015*
t	2.702	2.562

* Statistically Significant (p<0.050 Statistically Significant, p>0.050 Not Statistically Significant)


Cutometer Summary (N=32)
R0 (Firmness)
R5 (Elasticity)
0.6000
0.5000
0.4000
0.3000
0.2000
0.1000
0.0000
R VALUE
0.2966
0.5023
0.3326
0.5407
Baseline
1 Hour
TIMEPOINT



14. Conclusion:

Test material **Rejuvenating Anti-Wrinkle Serum Formula # SGF20055-00** (VCS Sample No.: SA201036; VCS Clinical Study No.: CS201033) tested under conditions stated herein, demonstrates the following:

Expert Grading results show an improvement of 13.64%, 7.14%, and 24.53% in the appearance of fine lines and wrinkles on the upper lip, nasolabial, and crow's feet, respectively, after 6 weeks of use. 1 Hour post single application of the test product shows a 12.05% improvement in skin firmness.

Cutometer results demonstrate improvement of skin elasticity by 7.65% and a decrease in skin firmness by -12.12%, after six weeks of use. Visioscan results show wrinkle reduction on crow's feet and nasolabial folds by 10.57% and 15.59%, respectively, after 6 weeks of use. Subjective questionnaire results show an overall positive perception of the effects of the product over six weeks of use.

Scanned panelist questionnaire comments and images are provided separately.

15. Authorization:

11/13/2020

JAMES VANZETTA, A.S.
Principal Investigator
DIRECTOR: Clinical Photography

DATE

11/13/2020

ANNA HARDY
Technical Personnel
CLINICAL RESEARCH MANAGER

DATE

11/13/2020

CHRYSTAL PLANETA, B.S.
Technical Personnel
SENIOR CLINICAL TECHNICIAN: Claims & Efficacy

DATE

11/16/2020

JANICE YALONG, M.S.
Technical Personnel
SENIOR CLINICAL TECHNICIAN: Claims & Efficacy

DATE

11/16/2020

SURINA CHOCK
Technical Personnel
CLINICAL TECHNICIAN: Claims & Efficacy

DATE

16. Quality Assurance Statement:

The Validated Claim Support, LLC Quality Assurance/Quality Control (QA/QC) unit is responsible for auditing the conduct, content and reporting of all clinical studies conducted at VCS.

This study has been conducted in accordance with Good Clinical Practices and other applicable laws and regulations, as well as VCS Standard Operating Procedures and study protocol (where applicable). Quality Assurance statement confirms the report accurately reflects data collected during the study. The study documentation was audited by the quality department personnel independent of the staff involved in the investigation.

The following VCS QA/QC representative signatures certify that all study pertinent data, records and documents, including this report, have been reviewed and are deemed to be acceptable, and conform to the requirements as indicated above.

Kornelia Grzybowska
zorrosign 5B1C55B907

11/16/2020

KORNELIA GRZYBOWSKA, M.S.
Quality Assurance
DIRECTOR: Quality

DATE

Bibi Tasmiya Masud
zorrosign 5B1C55B92F

11/17/2020

BIBI TASMIYA MASUD, B.A.
Quality Control
MANAGER: Quality

Date